NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
09 Oct 2012

TiGenix announces publication of Cx601 Phase I/IIa study in International Journal of Colorectal Disease

Leuven (BELGIUM) – October 9, 2012 – TiGenix (Euronext Brussels: TIG) announced today the publication in the International Journal of Colorectal Disease of the Phase I/II study of Cx601: Expanded allogeneic adipose-derived stems cells (eASCs) for the  treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase  I/II clinical trial.
25 Sep 2012

TiGenix’s new European production facility obtains EMA approval for commercial production of ChondroCelect

Leuven (BELGIUM) – September 25, 2012 – TiGenix (Euronext Brussels: TIG) announced today that after the successful cGMP inspection by the Dutch authorities earlier this year, it has now obtained the crucial approval from the European Medicines Agency (EMA) for the production of ChondroCelect, the company’s commercial cell therapy product for cartilage repair in the knee, in its new state-of-the-art manufacturing facility in Sittard Geleen (NL).
20 Sep 2012

TiGenix appoints Jean Stéphenne chairman & Russell Greig member of board of directors

Leuven (BELGIUM) – September 20, 2012 – TiGenix (Euronext Brussels: TIG) announcedtoday that the Company has appointed Jean Stéphenne as independent director and new chairman of the Company’s board of directors, and Russell Greig as independent director, in replacement of Koenraad Debackere and Mounia Chaoui-Roulleau, who resigned from the board.
24 Aug 2012

MedLumics Names Prof. Wolfgang Drexler President of its Scientific Advisory Board

MADRID, August 24, 2012 – MedLumics, a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology, has announced the appointment of world-renowned OCT expert Prof. Wolfgang Drexler as president of the company’s Scientific Advisory Board.
23 Aug 2012

TiGenix Business Update & Financial Highlights for the First Half of 2012

Leuven (BELGIUM) - August 23, 2012 -TiGenix NV (NYSE Euronext: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the half year ending June 30, 2012.
08 Aug 2012

TiGenix completes patient enrollment in Phase IIa rheumatoid arthritis study

Leuven (BELGIUM), Madrid (SPAIN) – August 8, 2012 – TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, announced today the completion of patient enrollment in the Company’s Phase IIa study of Cx611, a suspension of expanded allogeneic adult stem cells, in rheumatoid arthritis.
17 Jul 2012

TiGenix signs up 4th major hospital in the Netherlands for innovative cartilage repair therapy

Leuven (BELGIUM) – July 17, 2012 – TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, announced today that after obtaining national reimbursement for ChondroCelect in the Netherlands last month, the company has now contracted with four major hospitals to make its innovative cartilage repair therapy available to their patients on a routine basis: University Medical Center Utrecht, University Hospital Maastricht, Martini Hospital Groningen, and, most recently, the Elisabeth Hospital Tilburg.
10 Jul 2012

TiGenix enrolls first patients in pivotal Phase III trial with lead product Cx601 in perianal fistulas

Leuven (BELGIUM) – July 10, 2012 – TiGenix (NYSE Euronext: TIG) announced today theenrolment of the first patients in the ADMIRE-CD trial, its pivotal Phase III clinical trial with Cx601 in perianal fistulas in Crohn´s disease patients at Hospital Clínic, Barcelona, Spain.
02 Jul 2012

TiGenix reports positive results of Cx621 Phase I

Leuven (BELGIUM) – July 2, 2012 – TiGenix (NYSE Euronext: TIG) announced today that it has successfully completed the company’s Phase I clinical trial to assess the safety of intra-lymphatic administration of its expanded adipose stem cells product (Cx621).
Ysios Capital leads a € 2M Series A round of Inbiomotion<
28 Jun 2012

Ysios Capital leads a € 2M Series A round of Inbiomotion

The proceeds of the financing will be used to continue the validation of its proprietary biomarker in a number of clinical studies and advance its development.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.